Live from ASCO 2026: a preview
James & Sapna sent a brief message from ASCO 2026 about what they are looking forward to hearing at the meeting.OptimUM-02ADAMKN-942Neoadjuvant pilot studies... and more
1 Juni 6min
Ep 81: IGNYTE trial (RP1 + nivo)
SummaryThe conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into cli...
13 Feb 32min
Ep 80: 2025 Holiday Special
SummaryHappy Holidays and Festive Season Everyone! In this episode of Melanoma Matters, hosts Sapna Patel and James reflect on their "cultural" experiences over the past year, discussing movies, music...
30 Dec 202535min
Ep 79: coBRIM, COMBI-d 5-year follow-up
SummaryIn this episode of Melanoma Matters, James awaits an invitation to a film premiere (The Penguin Lessons) and we all await a picture of him in his tuxedo! Sapna and James go on to discuss the 5-...
29 Dec 202536min
Ep 78 TRAILER: MEK inhibitor trials
Enjoy this short trailer on MEK inhibitor monotherapy trials in melanoma
29 Dec 20251min
Ep 78: MEK inhibitor trials (METRIC, NEMO, pimasertib)
SummarySo many shoutouts in this episode of Melanoma Matters! Sapna and James engage in a lively discussion about MEK inhibitors as monotherapy treatment. They explore the METRIC, NEMO, and pimasertib...
29 Dec 202537min
Ep 77: Guest Merrick Ross
SummaryIn this episode of Melanoma Matters, hosts James Larkin and Sapna Patel engage with Merrick Ross, a seasoned surgical oncologist, discussing his background, the evolution of surgical practice w...
29 Dec 202544min
Ep 76: KEYNOTE 054 7-year follow-up
SummaryIn this Episode, hosts James & Sapna go into the 7-year follow-up from the randomized phase 3 adjuvant trial of pembrolizumab versus placebo for stage III melanoma, KEYNOTE-054There's a bit too...
28 Dec 202528min
